Docetaxel Combined with Intraperitoneal Fluorouracil Chemotherapy in Treatment of Advanced Gastric Cancer

Objective To evaluate the clinical efficacy and toxicity of docetaxel combined with intraperitoneal fluorouracil treatment in patients with advanced gastric cancer (AGC). Methods Thirty seven patients were treated with docetaxel (75mg/m2, iv, d1 and d8) and fluorouracil (1.0g,peritoneal perfusion,d2) every 3 weeks for 2~4 cycles. Results The total response rate to combination chemotherapy was 43.24% (16/37). Median time to progression (mTTP) was 5.3months. The clinical beneficial response was 78.38%(29/37).The main toxicity reaction includes hematological toxicity. The incidence of leucopenia was 72.97%. Conclusion Docetaxel combined with intraperitoneal fluorouracil in the treatment of advanced gastric cancer is effective and tolerable.